Milla Pharmaceuticals and Alter Pharma Group Receive FDA Approval for Dexmedetomidine Hydrochloride Injection

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, has received FDA approval for its generic version of Dexmedetomidine Hydrochloride Injection 4mcg/ml in 50mL and 100mL, which is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. The drug should be administered by continuous infusion not to exceed 24..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 11.
  • textsms

Milla Pharmaceuticals Inc. and Alter Pharma Group Receive FDA Approval for Dexmedetomidine Hydrochloride Injection

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, has received FDA approval for its generic version of Dexmedetomidine Hydrochloride Injection, which is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. The drug will be available in 50mL and 100mL and will help reduce recent supply issues experience..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 10.
  • textsms